Please assess the completion status of the following clinical trial:

Trial Title: Effects of Statin Therapy on Vascular Properties and Outcomes in Diastolic Heart Failure Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent,~* Age \> 18,~* Ejection fraction ≥ 50%,~* hospitalization for heart failure in the last 6 months and~* current NYHA Class II-IV symptoms, OR~* current NYHA Class III-IV symptoms and one of the following:~  1. ECG or echocardiographic evidence of moderate/severe left ventricular hypertrophy,~ 2. chest x-ray evidence of pulmonary congestion~Exclusion Criteria:~* Probable alternative cause of symptoms (pulmonary disease, severe anemia, etc.)~* Prior documented LVEF \< 40% or qualitative moderate or greater LV systolic dysfunction.~* Current indication for statin therapy~* Intolerance to statin therapy.~* Documented ischemic heart disease requiring lipid-lowering therapy (i.e. CAD, myocardial infarction, stroke)~* Evidence of significant myocardial ischemia on stress testing at screening visit.~* Evidence of hepatic abnormality (defined as liver enzymes \> 2 times the upper limit of normal values).~* Uncontrolled hypertension (BP \> 150/100)~* Significant valvular disease.~* Atrial fibrillation~* Known familial hypertrophic cardiomyopathy or obstructive hypertrophic cardiomyopathy.~* Restrictive cardiomyopathy or systemic illness known to be associated with infiltrative heart disease (i.e. amyloidosis, sarcoidosis, hemochromatosis).~* Cor pulmonale or other cause of right heart failure not related to LV dysfunction.~* Clinically significant pulmonary disease.~* Pericardial constriction or hemodynamically significant pleural effusion.~* Uncontrolled arrhythmia.~* Any systemic condition other than heart failure that may limit survival to less than 2 years.~* Advance renal disease (serum creatinine \> 3.0 mg/dl or on dialysis)~* Known intolerance or allergy to HMG CoA reductase inhibitors~* Uncontrolled hyper- or hypothyroidism.~* Any subject characteristic that may interfere with study compliance, such as baseline dementia, substance abuse, history of non-compliance with medications or appointments.~* Prisoners or other vulnerable populations.~* Any woman of child-bearing age with a documented positive pregnancy test.~* Subject is receiving therapy with other investigational therapy or is participating in any other clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Atorvastatin (Type: EXPERIMENTAL): Heart failure patients assigned to atorvastatin
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).